TY - JOUR
T1 - Clinical Impact of Tricuspid Regurgitation on Transcatheter Edge-to-Edge Mitral Valve Repair for Mitral Regurgitation
AU - Chitturi, Kalyan R.
AU - Bhardwaj, Bhaskar
AU - Murtaza, Ghulam
AU - Karuparthi, Poorna R.
AU - Faza, Nadeen N.
AU - Goel, Sachin S.
AU - Reardon, Michael J.
AU - Kleiman, Neal S.
AU - Aggarwal, Kul
N1 - Funding Information:
None.
Publisher Copyright:
© 2022
PY - 2022/8
Y1 - 2022/8
N2 - Objectives: This study aimed to evaluate whether baseline tricuspid regurgitation (TR) impacted clinical outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) for severe secondary mitral regurgitation (MR). Background: Baseline TR is common among patients undergoing M-TEER for secondary MR, although its impact on clinical outcomes is unclear. Methods: The Cochrane Library, PubMed/MEDLINE, and Google Scholar were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines from January 1, 2011 through January 31, 2021. Randomized controlled trials and nonrandomized prospective studies that evaluated baseline TR by echocardiography before M-TEER for MR were included. The primary outcome was a composite of mortality and heart failure hospitalization (HFH) at 1-year. Results: A total of 5 studies (n = 1395 patients) were included in the primary analysis. Concurrent moderate/severe TR was associated with a worse 1 year composite of all-cause mortality and HFH (OR: 2.13; 95% CI: 1.12–4.05; p = 0.02) after M-TEER for severe MR. In studies that reported TR grade pre- and post-M-TEER for severe MR, 32% of patients with moderate-to-severe baseline TR had a reduction in TR severity after the intervention. Conclusions: Baseline moderate-to-severe TR was associated with increased 1-year mortality and heart failure hospitalizations among patients undergoing M-TEER. Further randomized studies are needed to assess the interaction of TR among patients undergoing M-TEER.
AB - Objectives: This study aimed to evaluate whether baseline tricuspid regurgitation (TR) impacted clinical outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) for severe secondary mitral regurgitation (MR). Background: Baseline TR is common among patients undergoing M-TEER for secondary MR, although its impact on clinical outcomes is unclear. Methods: The Cochrane Library, PubMed/MEDLINE, and Google Scholar were searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines from January 1, 2011 through January 31, 2021. Randomized controlled trials and nonrandomized prospective studies that evaluated baseline TR by echocardiography before M-TEER for MR were included. The primary outcome was a composite of mortality and heart failure hospitalization (HFH) at 1-year. Results: A total of 5 studies (n = 1395 patients) were included in the primary analysis. Concurrent moderate/severe TR was associated with a worse 1 year composite of all-cause mortality and HFH (OR: 2.13; 95% CI: 1.12–4.05; p = 0.02) after M-TEER for severe MR. In studies that reported TR grade pre- and post-M-TEER for severe MR, 32% of patients with moderate-to-severe baseline TR had a reduction in TR severity after the intervention. Conclusions: Baseline moderate-to-severe TR was associated with increased 1-year mortality and heart failure hospitalizations among patients undergoing M-TEER. Further randomized studies are needed to assess the interaction of TR among patients undergoing M-TEER.
KW - Heart failure
KW - Mitral valve disease
KW - Percutaneous intervention
KW - Structural heart disease intervention
KW - Transcatheter edge-to-edge repair
KW - Tricuspid regurgitation
KW - Prospective Studies
KW - Humans
KW - Treatment Outcome
KW - Randomized Controlled Trials as Topic
KW - Mitral Valve Insufficiency/surgery
KW - Tricuspid Valve Insufficiency/surgery
KW - Heart Failure/therapy
UR - http://www.scopus.com/inward/record.url?scp=85127686883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127686883&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2022.01.027
DO - 10.1016/j.carrev.2022.01.027
M3 - Article
C2 - 35398010
AN - SCOPUS:85127686883
SN - 1553-8389
VL - 41
SP - 1
EP - 9
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
ER -